270 related articles for article (PubMed ID: 36316782)
1. Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity.
Huang J; Li M; Mei B; Li J; Zhu Y; Guo Q; Huang J; Zhang G
J Transl Med; 2022 Oct; 20(1):496. PubMed ID: 36316782
[TBL] [Abstract][Full Text] [Related]
2. A Peptide Mimetic of 5-Acetylneuraminic Acid-Galactose Binds with High Avidity to Siglecs and NKG2D.
Eggink LL; Spyroulias GA; Jones NG; Hanson CV; Hoober JK
PLoS One; 2015; 10(6):e0130532. PubMed ID: 26110603
[TBL] [Abstract][Full Text] [Related]
3. Siglec Signaling in the Tumor Microenvironment.
van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
Front Immunol; 2021; 12():790317. PubMed ID: 34966391
[TBL] [Abstract][Full Text] [Related]
4. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
5. Sialylation pattern in lung epithelial cell line and Siglecs expression in monocytic THP-1 cells as cellular indicators of cigarette smoke - induced pathology in vitro.
Wielgat P; Trofimiuk E; Czarnomysy R; Holownia A; Braszko JJ
Exp Lung Res; 2018 Apr; 44(3):167-177. PubMed ID: 29781747
[TBL] [Abstract][Full Text] [Related]
6. Tools to study and target the Siglec-sialic acid axis in cancer.
Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
[TBL] [Abstract][Full Text] [Related]
7. Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec-7.
Fan T; Liao Q; Zhao Y; Dai H; Song S; He T; Wang Z; Huang J; Zeng Z; Guo H; Zhang H; Qiu X
Cancer Sci; 2023 Feb; 114(2):370-383. PubMed ID: 36310398
[TBL] [Abstract][Full Text] [Related]
8. New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins.
Brinkman-Van der Linden EC; Varki A
J Biol Chem; 2000 Mar; 275(12):8625-32. PubMed ID: 10722702
[TBL] [Abstract][Full Text] [Related]
9. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
[TBL] [Abstract][Full Text] [Related]
10. Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers.
Bordoloi D; Kulkarni AJ; Adeniji OS; Pampena MB; Bhojnagarwala PS; Zhao S; Ionescu C; Perales-Puchalt A; Parzych EM; Zhu X; Ali AR; Cassel J; Zhang R; Betts MR; Abdel-Mohsen M; Weiner DB
Sci Adv; 2023 Nov; 9(44):eadh4379. PubMed ID: 37910620
[TBL] [Abstract][Full Text] [Related]
11. GATA3 Encapsulated by Tumor-Associated Macrophage-Derived Extracellular Vesicles Promotes Immune Escape and Chemotherapy Resistance of Ovarian Cancer Cells by Upregulating the CD24/Siglec-10 Axis.
Chen C; Zhang L; Ruan Z
Mol Pharm; 2023 Feb; 20(2):971-986. PubMed ID: 36547230
[TBL] [Abstract][Full Text] [Related]
12. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
13. Dual actions of group B
Uchiyama S; Sun J; Fukahori K; Ando N; Wu M; Schwarz F; Siddiqui SS; Varki A; Marth JD; Nizet V
Proc Natl Acad Sci U S A; 2019 Apr; 116(15):7465-7470. PubMed ID: 30910970
[TBL] [Abstract][Full Text] [Related]
14. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
15. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
[TBL] [Abstract][Full Text] [Related]
16. Assessment of sialic acid diversity in cancer- and non-cancer related CA125 antigen using sialic acid-binding Ig-like lectins (Siglecs).
Mitic N; Milutinovic B; Jankovic M
Dis Markers; 2012; 32(3):187-94. PubMed ID: 22377735
[TBL] [Abstract][Full Text] [Related]
17. Sensing the neuronal glycocalyx by glial sialic acid binding immunoglobulin-like lectins.
Linnartz-Gerlach B; Mathews M; Neumann H
Neuroscience; 2014 Sep; 275():113-24. PubMed ID: 24924144
[TBL] [Abstract][Full Text] [Related]
18. Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2.
Wieboldt R; Sandholzer M; Carlini E; Lin CW; Börsch A; Zingg A; Lardinois D; Herzig P; Don L; Zippelius A; Läubli H; Mantuano NR
Cell Mol Immunol; 2024 May; 21(5):495-509. PubMed ID: 38448555
[TBL] [Abstract][Full Text] [Related]
19. Unraveling Molecular Recognition of Glycan Ligands by Siglec-9 via NMR Spectroscopy and Molecular Dynamics Modeling.
Atxabal U; Nycholat C; Pröpster JM; Fernández A; Oyenarte I; Lenza MP; Franconetti A; Soares CO; Coelho H; Marcelo F; Schubert M; Paulson JC; Jiménez-Barbero J; Ereño-Orbea J
ACS Chem Biol; 2024 Feb; 19(2):483-496. PubMed ID: 38321945
[TBL] [Abstract][Full Text] [Related]
20. Sialic Acid-Siglec-E Interactions During
Mukherjee K; Khatua B; Mandal C
Front Immunol; 2020; 11():332. PubMed ID: 32184783
[No Abstract] [Full Text] [Related]
[Next] [New Search]
